M · L · J
Mengyu Lu, Justin Zhou, Sierra Tao, Claire Chen
February 23, 2026
Kirkland Assists Ascletis Pharma on its Share Placing
1 min
AI-made summary
- • Kirkland & Ellis advised Ascletis Pharma Inc
- on the placement of 69,256,000 shares
- • The placement was announced on February 3, 2026, and completed on February 10, 2026
- • Citigroup Global Markets Limited acted as the sole placing agent for the transaction
- • The net proceeds from the placement are expected to be approximately HK$835.3 million after commissions and expenses
- • The Kirkland team included capital markets lawyers Mengyu Lu, Justin Zhou, Sierra Tao, and Claire Chen.
Kirkland & Ellis represented Ascletis Pharma Inc. (Ascletis Pharma, Stock Code: 1672) on its placing of 69,256,000 shares. The Placing was announced on February 3, 2026 and completed on February 10, 2026. Citigroup Global Markets Limited acts as its sole placing agent. The net proceeds (after deducting the commissions and estimated expenses) from the Placing are expected to be approximately HK$835.3 million in aggregate. Read the transaction announcement The Kirkland team included capital markets lawyers Mengyu Lu, Justin Zhou, Sierra Tao and Claire Chen.
M
Article Author
Mengyu Lu, Justin Zhou, Sierra Tao, Claire Chen
The Sponsor